N

Neuphoria Therapeutics Inc
NASDAQ:NEUP

Watchlist Manager
Neuphoria Therapeutics Inc
NASDAQ:NEUP
Watchlist
Price: 4.02 USD 0.25%
Market Cap: $21.6m

Neuphoria Therapeutics Inc
Research & Development

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Neuphoria Therapeutics Inc
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
N
Neuphoria Therapeutics Inc
NASDAQ:NEUP
Research & Development
-$9m
CAGR 3-Years
8%
CAGR 5-Years
-18%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Research & Development
-$8.8B
CAGR 3-Years
-10%
CAGR 5-Years
-8%
CAGR 10-Years
-8%
Gilead Sciences Inc
NASDAQ:GILD
Research & Development
-$5.8B
CAGR 3-Years
-2%
CAGR 5-Years
-1%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Research & Development
-$6.8B
CAGR 3-Years
-15%
CAGR 5-Years
-10%
CAGR 10-Years
-5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Research & Development
-$3.9B
CAGR 3-Years
-16%
CAGR 5-Years
-16%
CAGR 10-Years
-16%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Research & Development
-$5.2B
CAGR 3-Years
-16%
CAGR 5-Years
-15%
CAGR 10-Years
-13%
No Stocks Found

Neuphoria Therapeutics Inc
Glance View

Market Cap
21.6m USD
Industry
Biotechnology

Neuphoria Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Burlington, Massachusetts and currently employs 8 full-time employees. Neuphoria Therapeutics Inc. is a clinical-stage biotechnology company. The firm is focused on developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute, as needed treatment of social anxiety disorder (SAD) and for chronic treatment of post-traumatic stress disorder (PTSD). BNC210 is a first-of-its-kind, well-tolerated, broad spectrum anti-anxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. Its pipeline also includes the α7 nicotinic acetylcholine receptor next generation and the Kv3.1/3.2 preclinical programs, both in the lead optimization development stage.

NEUP Intrinsic Value
7.72 USD
Undervaluation 48%
Intrinsic Value
Price
N

See Also

What is Neuphoria Therapeutics Inc's Research & Development?
Research & Development
-9m USD

Based on the financial report for Jun 30, 2025, Neuphoria Therapeutics Inc's Research & Development amounts to -9m USD.

What is Neuphoria Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-18%

Over the last year, the Research & Development growth was 4%. The average annual Research & Development growth rates for Neuphoria Therapeutics Inc have been 8% over the past three years , -18% over the past five years .

Back to Top